Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis

IRVINE, California, February 5, 2018 – Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Company”), the world’s leading temperature controlled logistics company dedicated to the life sciences industry, today announced that Cryoport will support TiGenix (Euronext Brussels and NASDAQ: TIG) as it conducts its SEPCELL phase Ib/IIa clinical study to evaluate the safety and efficacy of expanded Cx611 allogeneic adipose‐derived stem cells (eASCs) for the treatment of sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care unit.

TiGenix, a global leader in allogeneic stem cell therapies targeting autoimmune diseases, aims to recruit 180 patients in at least 50 centers for the randomized double-blind placebo controlled SEPCELL study. As a part of the agreement between the companies, Cryoport will provide global logistics support, observing international best practices for transporting cryogenically preserved clinical commodities.  Cryoport’s suite of unique temperature controlled logistics solutions includes its Cryoport Express® shippers, SmartPak II™ Condition Monitoring System, Cryoportal™ Logistics Management Platform and 24/7/365 logistics support. These unparalleled capabilities will enable TiGenix to monitor its shipments and track the conditions and location of its stem cells while in transit, around the clock.

Jerrell Shelton, Chief Executive Officer of Cryoport, Inc., commented, “Sepsis is a potentially life-threatening complication of infection, which can lead to systemic inflammation and, in the worst cases, organ failure. The emergence of increasingly drug-resistant bacteria, alongside aging populations around the world, is driving a growing number of sepsis cases. TiGenix aims to leverage the anti-inflammatory properties found in stem cells to develop a novel treatment for sepsis, using its allogeneic (donor derived) stem cell platform, Cx611. We are, indeed, proud to be providing logistics support for this exciting clinical trial.”

About Cryoport, Inc.

Cryoport is the life sciences industry’s most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

  • simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
  • delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
  • providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Transition Report on Form 10-K for the nine months ended December 31, 2016 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Investor Contacts:

Todd Fromer/Elizabeth Barker

tfromer@kcsa.com/ebarker@kcsa.com

P: 1 212-682-6300

Tailwinds' Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit http://tailwindsresearch.com/disclaimer/.

LEAVE A REPLY